BCL2 and diffuse large B-cell lymphoma: DLBCL patients with MYC and BCL2 overexpression had a shorter OS (median of 5.1 vs. 13.7 months) and a lower ORR (14.8% vs. 46.2%) compared to normal expression levels [104].